8-K: OpGen Regains Minimum Bid Price Compliance but Faces Stockholders' Equity Delisting Notice

OpGen, Inc. has regained compliance with Nasdaq's minimum bid price rule but is now facing a delisting notice due to not meeting the minimum stockholders' equity requirement.

Summary

• OpGen, Inc. received a notice from Nasdaq on June 5, 2023, stating that its common stock failed to maintain a minimum bid price of $1.00 per share.
• The company appealed this determination and was granted an extension to regain compliance.
• On June 5, 2024, Nasdaq notified OpGen that it had regained compliance with the minimum bid price rule.
• However, on the same day, OpGen received another notice from Nasdaq stating that it does not meet the minimum stockholders' equity requirement for continued listing.
• Nasdaq requires companies to maintain stockholders' equity of at least $2,500,000 or meet alternative criteria.
• OpGen submitted a response to Nasdaq on June 11, 2024, outlining its plan to address the stockholders' equity deficiency.
• There is no guarantee that Nasdaq will grant additional time or that OpGen will be able to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the new delisting notice related to stockholders' equity, despite regaining compliance with the minimum bid price rule. This indicates ongoing financial challenges and uncertainty about the company's future listing status.

Positives

• OpGen successfully regained compliance with the Nasdaq minimum bid price rule.

Negatives

• OpGen is not in compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq.
• There is no assurance that Nasdaq will grant additional time to cure the deficiency.
• There is no guarantee that OpGen will be able to regain compliance with the stockholders' equity requirement.

Risks

• There is a risk that Nasdaq may not grant OpGen additional time to cure the stockholders' equity deficiency.
• There is a risk that OpGen may not be able to regain compliance with the Nasdaq listing requirements.
• Failure to regain compliance could result in the delisting of OpGen's securities from the Nasdaq Capital Market.

Future Outlook

The company intends to regain compliance with Nasdaq's listing rules, but there is no guarantee of success. The company does not undertake any obligation to publicly update or revise any forward-looking statement.

Management Comments

• The company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding the stockholders' equity delinquency and the company's plan to cure such delinquency.

Industry Context

This announcement highlights the challenges faced by smaller companies in maintaining listing compliance on major exchanges like Nasdaq, particularly in volatile market conditions. It is not uncommon for companies to face delisting notices due to share price or equity issues.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially those with volatile stock prices and limited revenue.
• Companies like OpGen often rely on capital raises to maintain operations and meet listing requirements, which can be difficult in challenging market conditions.
• The minimum stockholders' equity requirement of $2.5 million is a standard benchmark for Nasdaq Capital Market listings, and failure to meet this is a common reason for delisting notices.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in share value.
• Employees may experience uncertainty regarding the company's future.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• OpGen needs to successfully execute its plan to address the stockholders' equity deficiency.
• The company will await a decision from the Nasdaq Hearings Panel regarding its plan.
• OpGen may need to explore additional measures to ensure continued listing on Nasdaq.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, stockholders' equity, compliance, listing rule, OPGN